- Home
- FLYX vs NKTX Comparison
FLYX vs NKTX Comparison
Compare FLYX & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYX
- NKTX
- Stock Information
- Founded
- FLYX 2015
- NKTX 2015
- Country
- FLYX United States
- NKTX United States
- Employees
- FLYX N/A
- NKTX N/A
- Industry
- FLYX Blank Checks
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FLYX Finance
- NKTX Health Care
- Exchange
- FLYX Nasdaq
- NKTX Nasdaq
- Market Cap
- FLYX 190.6M
- NKTX 225.1M
- IPO Year
- FLYX N/A
- NKTX 2020
- Fundamental
- Price
- FLYX $2.18
- NKTX $2.45
- Analyst Decision
- FLYX Hold
- NKTX Strong Buy
- Analyst Count
- FLYX 1
- NKTX 5
- Target Price
- FLYX N/A
- NKTX $17.00
- AVG Volume (30 Days)
- FLYX 22.4K
- NKTX 1.2M
- Earning Date
- FLYX 01-01-0001
- NKTX 11-07-2024
- Dividend Yield
- FLYX N/A
- NKTX N/A
- EPS Growth
- FLYX N/A
- NKTX N/A
- EPS
- FLYX N/A
- NKTX N/A
- Revenue
- FLYX $311,873,000.00
- NKTX N/A
- Revenue This Year
- FLYX $15.91
- NKTX N/A
- Revenue Next Year
- FLYX $39.64
- NKTX N/A
- P/E Ratio
- FLYX N/A
- NKTX N/A
- Revenue Growth
- FLYX N/A
- NKTX N/A
- 52 Week Low
- FLYX $1.79
- NKTX $2.38
- 52 Week High
- FLYX $24.21
- NKTX $16.24
- Technical
- Relative Strength Index (RSI)
- FLYX 39.12
- NKTX 26.80
- Support Level
- FLYX $2.05
- NKTX $2.40
- Resistance Level
- FLYX $2.28
- NKTX $3.81
- Average True Range (ATR)
- FLYX 0.18
- NKTX 0.25
- MACD
- FLYX 0.03
- NKTX -0.02
- Stochastic Oscillator
- FLYX 67.11
- NKTX 4.90
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 90 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.